SLT not best for PEXG patients

Article

Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.

Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.

Mauro Cellini of the Department of Surgery Science and Anaesthesiology, Ophthalmology Service, University of Bologna, Italy and colleagues evaluated changes in metalloproteinases (MMP-2) and tissue inhibitor of metalloproteinases (TIMP-2) in PEXG patients by assessing the concentrations in the aqueous humour of MMP-2 and TIMP-2 after phacoemulsification in PEXG with cataract patients (n=15) and after SLT in PEXG patients (n=15), and compared these levels with those of the control group (n=15).

Before SLT treatment, patients had a mean IOP of 25.8±1.9 mmHg. Following SLT treatment, IOP initially dropped but then rebounded to pre-treatment levels, necessitating trabeculectomy: at day 10, IOP was 18.1±1.4 mmHg; at 31.5±7.6 days, IOP was 25.4±1.6 mmHg. In these patients, MMP-2 and TIMP-2 were 58.52±9.66 µg/ml and 105.96±27.65 µg/ml, respectively. In PEXG with cataract patients, these levels were 57.77±9.25 µg/ml and 105.19±28.53 µg/ml, respectively. The ratio of MMP-2 to TIMP-2 was 1.87:0.64 in the PEXG group, 1.88:0.65 in the PEXG with cataract group and 1.11:0.44 in control subjects.

The researchers concluded that this increase in the MMP-2/TIMP-2 ratio may be associated with any IOP increase that occurs after SLT in PEXG patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.